News round-up for 9-13 June by DDW Senior Digital Content Editor Diana Spencer.

This week’s round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer’s gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on haemophilia gene therapy patients.

The top stories:

Alzheimer’s gene therapy shows promise in preserving brain function

Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function.

Read more…

Novel single-gene target reverses cellular ageing

Biotechnology company Shift Bioscience has published new research identifying a novel, single-gene target for cellular rejuvenation.

Read more…

Data shows improved quality of life with CFTR modulators

Vertex Pharmaceuticals has shared data demonstrating the positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and in particular, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor).

Read more…

Haemophilia gene therapy patients thriving a decade later

Patients who received a one-off gene therapy to treat haemophilia are still doing well up to 13 years later, finds a new study from researchers at University College London (UCL), the Royal Free Hospital and St Jude Children’s Research Hospital, Tennessee.

Read more…

SpliceBio secures $135m to advance gene therapy candidates

SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.

Read more…